Zhimei Wang
Zhimei Wang, MS, DABT is Director of Toxicology at WuXi AppTec and leads the Study Director Group for the company’s Nantong site Toxicology Department. With more than 14 years of non-clinical drug safety evaluation, she has gained extensive experience in non-clinical research across various fields, including small molecules, peptides, oligonucleotides, proteins, antibody/prodrug/ADC, LNP, viral and cell therapy products. Zhimei provides technical support and assists in safety evaluation studies for IND and NDA/BLA submissions. In 2023, she obtained a Diplomate of the American Board of Toxicology certification.
ArticlePeptides in practice: what it takes to advance these therapies to clinic
Peptide therapeutics are emerging as a powerful class of medicines capable of targeting diseases that challenge traditional modalities. This article reveals their rising clinical impact and the key development, safety and translational challenges that must be addressed to bring them successfully to patients.